| Detected | Trial | Change |
|---|---|---|
| 2026-06-10 | NCT07555470 Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma |
Recruitment opened |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT07372352 | Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL | Peripheral T Cells Lymphoma (PTCL) | Recruiting |
| NCT07294664 | PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line… | Advanced Gastric Cancer | Recruiting |
| NCT07555470 | Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma | Follicular Lymphoma | Recruiting |
| Phase 1/2 | |||
| NCT07339527 | EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or… | Mature T-cell and NK-cell Lymphoma | Not Yet Recruiting |
| NCT07502768 | Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Not Yet Recruiting |